• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

自体造血干细胞移植（SCT）后复发的所有霍奇金淋巴瘤患者是否都应考虑异体 SCT？

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?

机构信息

University College London Cancer Institute, London, United Kingdom.

出版信息

Blood Adv. 2018 Apr 10;2(7):817-820. doi: 10.1182/bloodadvances.2017011122.

DOI:10.1182/bloodadvances.2017011122
PMID:29636327
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5894255/
Abstract

This article has a companion Counterpoint by Moskowitz.

摘要

本文有一篇由 Moskowitz 撰写的相关反论文章。

相似文献

1
Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?自体造血干细胞移植（SCT）后复发的所有霍奇金淋巴瘤患者是否都应考虑异体 SCT？
Blood Adv. 2018 Apr 10;2(7):817-820. doi: 10.1182/bloodadvances.2017011122.
2
Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily.对于所有 ASCT 后复发的 HL 患者，是否都应考虑进行同种异体 SCT？需要咨询，但是不一定需要移植。
Blood Adv. 2018 Apr 10;2(7):821-824. doi: 10.1182/bloodadvances.2017011130.
3
Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.复发/难治性霍奇金淋巴瘤的挽救治疗：同种异体移植、维布妥昔单抗及新型药物的作用
Expert Opin Biol Ther. 2016;16(3):347-64. doi: 10.1517/14712598.2015.1130821. Epub 2016 Feb 6.
4
Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.非霍奇金淋巴瘤的造血干细胞移植
Hematol Oncol Clin North Am. 2014 Dec;28(6):1073-95. doi: 10.1016/j.hoc.2014.08.015. Epub 2014 Sep 22.
5
Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.在复发/难治性CD30阳性淋巴细胞增殖性疾病中，使用本妥昔单抗作为异基因干细胞移植前的挽救治疗：单中心经验。
Intern Med J. 2017 May;47(5):574-578. doi: 10.1111/imj.13415.
6
Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.移植前（18）F-氟脱氧葡萄糖-正电子发射断层扫描对霍奇金淋巴瘤T细胞去除异基因移植后生存结果的影响
Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14.
7
How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT.如何治疗自体造血干细胞移植后复发的霍奇金淋巴瘤患者：异基因造血干细胞移植
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):26-33. doi: 10.1016/j.clml.2017.11.003. Epub 2017 Dec 9.
8
Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.采用简化方法的难治性或复发性淋巴瘤患者门诊接受低强度异基因干细胞移植与自体干细胞移植的比较。
Ann Hematol. 2010 Oct;89(10):1045-52. doi: 10.1007/s00277-010-0986-1. Epub 2010 May 21.
9
Stem cell transplantation in Hodgkin lymphoma.霍奇金淋巴瘤中的干细胞移植
Hematol Oncol Clin North Am. 2014 Dec;28(6):1097-112. doi: 10.1016/j.hoc.2014.08.011. Epub 2014 Sep 26.
10
High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party.高剂量化疗和自体造血干细胞移植治疗结节性淋巴细胞为主型霍奇金淋巴瘤：欧洲血液和骨髓移植学会-淋巴瘤工作组的回顾性研究。
Am J Hematol. 2018 Jan;93(1):40-46. doi: 10.1002/ajh.24927. Epub 2017 Nov 9.

引用本文的文献

1
Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma.复发/难治性霍奇金淋巴瘤患者异基因干细胞移植的结局
Curr Oncol. 2025 Feb 18;32(2):118. doi: 10.3390/curroncol32020118.
2
Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.经典型霍奇金淋巴瘤：从过去到未来——发病机制和治疗进展的综合综述。
Int J Mol Sci. 2023 Jun 13;24(12):10095. doi: 10.3390/ijms241210095.
3
Allogeneic stem cell transplant in relapsed/ refractory Hodgkin lymphoma: A 21 years' experience.异基因干细胞移植治疗复发/难治性霍奇金淋巴瘤：21年经验
Porto Biomed J. 2022 Oct 24;7(5):e173. doi: 10.1097/j.pbj.0000000000000173. eCollection 2022 Sep-Oct.
4
Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches.经典型霍奇金淋巴瘤的管理：审视最新证据及当前治疗方法
Exp Hematol Oncol. 2022 Dec 27;11(1):108. doi: 10.1186/s40164-022-00360-4.
5
Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: Recent Advances and Outcomes.重新评估异基因造血干细胞移植在复发难治性霍奇金淋巴瘤中的作用：近期进展与结果
J Pers Med. 2022 Jan 18;12(2):125. doi: 10.3390/jpm12020125.
6
The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma.异基因干细胞移植前实现完全缓解对霍奇金淋巴瘤无进展生存期的影响。
Clin Hematol Int. 2021 Jul 15;3(3):116-118. doi: 10.2991/chi.k.210704.002. eCollection 2021 Sep.
7
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.复发性/难治性霍奇金淋巴瘤的治疗效果优化：当前及未来治疗策略综述
Ther Adv Hematol. 2020 Feb 16;11:2040620720902911. doi: 10.1177/2040620720902911. eCollection 2020.
8
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.allo-HSCT 治疗初治霍奇金淋巴瘤患者：一项单臂、多中心研究。
Blood Adv. 2019 Dec 23;3(24):4264-4270. doi: 10.1182/bloodadvances.2019001016.
9
Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment.异基因干细胞移植可提高复发型霍奇金淋巴瘤患者在挽救治疗后实现完全缓解的生存率。
Bone Marrow Transplant. 2020 Jan;55(1):117-125. doi: 10.1038/s41409-019-0640-z. Epub 2019 Aug 21.
10
Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.自体移植失败后，采用TLI-ATG预处理的异基因移植治疗霍奇金淋巴瘤。
Blood Adv. 2018 Jul 10;2(13):1547-1550. doi: 10.1182/bloodadvances.2018021071.

本文引用的文献

1
Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.移植后环磷酰胺为基础的单倍体相合移植作为霍奇金淋巴瘤同胞或无关供者移植的替代方案：欧洲血液和骨髓移植学会淋巴瘤工作组的注册研究。
J Clin Oncol. 2017 Oct 20;35(30):3425-3432. doi: 10.1200/JCO.2017.72.6869. Epub 2017 Aug 28.
2
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.霍奇金淋巴瘤 1.2017 年版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2017 May;15(5):608-638. doi: 10.6004/jnccn.2017.0064.
3
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.帕博利珠单抗治疗复发/难治性经典型霍奇金淋巴瘤的疗效和安全性II期研究。
J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25.
4
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.异基因造血干细胞移植后纳武利尤单抗治疗复发霍奇金淋巴瘤的疗效和耐受性。
Blood. 2017 May 4;129(18):2471-2478. doi: 10.1182/blood-2016-11-749556. Epub 2017 Mar 7.
5
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.复发/难治性淋巴瘤患者接受PD-1阻断治疗后进行异基因造血干细胞移植的安全性和有效性
Blood. 2017 Mar 9;129(10):1380-1388. doi: 10.1182/blood-2016-09-738385. Epub 2017 Jan 10.
6
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.纳武利尤单抗用于自体干细胞移植和维布妥昔单抗均治疗失败后的经典型霍奇金淋巴瘤：一项多中心、多队列、单臂2期试验。
Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.
7
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.复发或难治性霍奇金淋巴瘤患者使用维布妥昔单抗的5年生存率和疗效持久性结果
Blood. 2016 Sep 22;128(12):1562-6. doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18.
8
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.在接受维布妥昔单抗治疗失败的经典型霍奇金淋巴瘤患者中使用帕博利珠单抗进行程序性死亡-1阻断治疗。
J Clin Oncol. 2016 Nov 1;34(31):3733-3739. doi: 10.1200/JCO.2016.67.3467.
9
Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.移植前（18）F-氟脱氧葡萄糖-正电子发射断层扫描对霍奇金淋巴瘤T细胞去除异基因移植后生存结果的影响
Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14.
10
Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.细胞毒性疗法联合造血细胞移植在霍奇金淋巴瘤治疗中的作用：美国血液和骨髓移植学会指南
Biol Blood Marrow Transplant. 2015 Jun;21(6):971-83. doi: 10.1016/j.bbmt.2015.02.022. Epub 2015 Mar 12.